Prostate Cancer News and Research RSS Feed - Prostate Cancer News and Research Twitter

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Further Reading
OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

The Ontario Health Technology Advisory Committee has recommended Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU or MRgFUS) as a possible "cost-effective strategy" and a "safe and effective, noninvasive, uterine-preserving" option for women seeking treatment for uterine fibroids. [More]
Men who receive brachytherapy more likely to be cancer-free five years later

Men who receive brachytherapy more likely to be cancer-free five years later

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. [More]
Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Dan Theodorescu awarded Barringer Medal for distinguished contributions to urology

Dan Theodorescu, MD, PhD, director of the NCI-designated University of Colorado Cancer Center and professor of Urology and Pharmacology at the University of Colorado School of Medicine was awarded the Barringer Medal this past Saturday from the American Association of Genitourinary Surgeons for his distinguished contributions to urology. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers. [More]
AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostic professionals, today published a special article in The Journal of Molecular Diagnostics titled, "Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?" The report provides a thorough overview of research to-date on the minimally invasive "liquid biopsy" approaches to cancer diagnostics. [More]
Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Oral MCP enhances anti-cancer, anti-metastatic effects of radiation therapy in prostate cancer treatment

Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. [More]
Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample. [More]
Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from BRCA-targeting drug

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday). [More]
Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration. [More]
Blue Cross Blue Shield of Michigan, UMHS collaborate to improve quality of care for Michiganians

Blue Cross Blue Shield of Michigan, UMHS collaborate to improve quality of care for Michiganians

Blue Cross Blue Shield of Michigan and the University of Michigan Health System will collaborate with emergency physicians at participating hospitals across the state to develop best practices to improve the experience and outcomes of patients receiving care in emergency departments. [More]
Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

The American Association for Cancer Research will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor (AR) Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
PCF announces Stupski Prize in Prostate Cancer Computational Oncology

PCF announces Stupski Prize in Prostate Cancer Computational Oncology

The Prostate Cancer Foundation is pleased to announce the Stupski Prize in Prostate Cancer Computational Oncology, a first-in-field initiative designed to attract novel ideas to the rapidly changing field of large-scale cancer bioinformatics. [More]
New Commission outlines current state of research into sepsis

New Commission outlines current state of research into sepsis

Leading doctors today [Monday 20 April, 2015] warn that medical and public recognition of sepsis--thought to contribute to between a third and a half of all hospital deaths--must improve if the number of deaths from this common and potentially life-threatening condition are to fall. [More]
Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency can activate Hedgehog signaling pathway

Zinc deficiency - long associated with numerous diseases, e.g. autism, lung cancer, prostate cancer, and ovarian cancers - can lead to activation of the Hedgehog signaling pathway, a biomolecular pathway that plays essential roles in developing organisms and in diseases, according to new research at Rensselaer Polytechnic Institute. [More]
Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

Donald S. Coffey to receive Margaret Foti Award at AACR Annual Meeting 2015

Donald S. Coffey, PhD, will be honored with the ninth annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
Obesity in African-American men increases prostate cancer risk

Obesity in African-American men increases prostate cancer risk

Obesity has a profoundly different effect on prostate cancer risk in African-American as compared to non-Hispanic white men. Obesity in black men substantially increases the risk of low- and high-grade prostate cancer, while obesity in white men moderately reduces the risk of low-grade cancer and only slightly increases the risk of high-grade cancer, according to the first large, prospective study to examine how race and obesity jointly affect prostate cancer risk. [More]
Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Non-vigorous walking may help prostate cancer survivors reduce damaging side effects

Walking at an easy pace for about three hours every week may be just enough physical activity to help prostate cancer survivors reduce damaging side effects of their treatment, according to a new Northwestern Medicine study. [More]
Itraconazole drug shows potential in cancer treatment

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience. [More]
Advertisement
Advertisement